Gómez-Márquez JJ. Polendo-Villarreal JA, Luna-Cruz B, Ruiz-Valverde P, Osornio-Rodríguez M

Language: Spanish
References: 6
Page: 152-156
PDF size: 94.40 Kb.

ABSTRACT

Background: Post-surgical pain is a kind of acute nociceptive pain which persists until healing, but it may be relieved with anti-inflammatory analgesics. Parecoxib is an inhibitor of endoperoxidase H-2 which may offer a new alternative. Material and methods: Fifty patients undergoing cholecystectomy and hysterectomy were divided into two groups: PX (parecoxib) (n = 25), and MZ (metamizole) (n = 25). All surgery was performed under general anesthesia. In the recovery room, with a score of two in the Ramsay scale and ≥ 4 in the visual analogue scale (VAS), patients received either parecoxib 40 mg or metamizole 2 g. Pain was evaluated hourly. If it was similar or greater that at baseline, rescue medication was used (buprenorphine,0.002 mg/kg). Student´s t test and variance analysis were used for statistical analysis. Results: No statistically significant differences were found among the two groups. A statistical decrease in pain was seen in 23 patients in the PX Group; 69% required rescue analgesia. In the MZ Group, a statistical decrease in pain was seen in the fourth measurement; 95% required rescue analgesia. Discussion: Pain after cholecystectomy and hysterectomy is poorly controlled with metamizole. A more specific analgesic, such as parecoxib, is clearly necessary.

REFERENCES

1. Ceraso O, Aldrete A. Fisiología del dolor y sus teorías de acción. Tratado de Algología. Ed. Dr José Antonio Aldrete. JGH Editores. 1999;1:61-79.

2. Farrar M, Lerman J. Conceptos novedosos sobre analgesia en pacientes pediátricos quirúrgicos. Clínicas de Anestesiología de Norteamérica 2002;1:57-78.

3. Aldrete A, Aldrete J. Analgésicos no opiáceos. En: J. Antonio Aldrete, Editor. Tratado de Algología. México D.F. JGH Editores. 1999;10:757-770.

4. Camu F, Beecher T, Recker D, Verburg K. Valdecoxib, an specific inhibitor of COX-2, is an efficient analgesic that lowers the necessity of opiaceous in the treatment of patients under arthroplasty of hip. Am J of Therapeutics 2002;9:43-51.

5. Ibrahim A. Effects of Parecoxib, a parenteral COX-2 specific inhibitor, on the pharmacokinetic of propofol. Anesthesiology 2002;96:88-95.

6. Langland F. A comparative analgesic efficacy study of parecoxib, a new COX-2 specific inhibitor, in post-gynecologic surgery patients. Poster presented at American Pain Society, Atlanta, Georgia, Nov 3, 2000.